Aduro Biotech Inc

Aduro Biotech — Investor Presentation (January 2019)

30 slides from Aduro Biotech's investor presentation, Jan 7, 2019

  1. Slide 1: Corporate Presentation January 2019

    Corporate Presentation January 2019 P I O N E E R I N G I M M U N O T H E R A P Y . T R A N S F O R M I N G L I V E S .

  2. Slide 2: Note Regarding Forward-Looking Statements

    Note Regarding Forward-Looking Statements This presentation and the accompanying oral presentation include express and implied forward-looking statements regarding the current intentions, expectations, estimates, opinions and beliefs of Aduro Biotech, Inc. (“Aduro”) that are not historical facts. Th

  3. Slide 3: Note Regarding Forward-Looking Statements

    Note Regarding Forward-Looking Statements intentions, This presentation expectations, and the estimates, accompanying opinions oral and presentation beliefs of include Aduro Biotech, express Inc. and (“Aduro”) implied forward-looking that are not historical statements facts. regarding These forward-

  4. Slide 4: Focus of Aduro Pipeline

    Focus of Aduro Pipeline Program Target Indication Discovery Preclinical Phase 1 Phase 2 Partner ADU-S100 (MIW815) STING Multiple tumors ADU-S100 + spartalizumab STING Multiple tumors ADU-S100 STING + ipilimumab STING Melanoma ADU-S100 Head & Neck + anti-PD-1 STING (planned) cGAS-STING pathway cGAS-S

  5. Slide 5: ADU-S100 STING Agonist

    ADU-S100 y STING Agonist ~ Seal _ ADUR' BIOTEC.

  6. Slide 6: STING Plays a Critical Role in Activation of Tumor Immunity

    STING Plays a Critical Role in Activation of Tumor Immunity • STimulator of INterferon Genes (STING) is a critical component of an innate immune pathway – STING protein function activated by cyclic dinucleotides – Immediate production of type I IFN and innate immunity – IFN-β is a signature cytokin

  7. Slide 7: Key Attributes of ADU-S100 (MIW815)

    Key Attributes of ADU-S100 (MIW815) First-in-Class STING Agonist • Demonstrated preclinical anti-tumor activity – Induces local innate immune activation – cytokine production – in injected tumors – Activates tumor-specific CD8+ T cells and systemic tumor rejection, bridging innate to adaptive immuni

  8. Slide 8: Advancing ADU-S100 (MIW815) Clinical Development

    Advancing ADU-S100 (MIW815) Clinical Development First-in-human clinical experience in heavily pre-treated patients with a diverse set of advanced cancers Monotherapy + spartalizumab + ipilimumab + anti-PD1 (ongoing) (ongoing) (enrolling) (planned) • First in human • Proof of concept • Demonstrate •

  9. Slide 9: ADU-S100 (MIW815) Monotherapy Trial Dose Escalation

    Phase 1 ADU-S100 (MIW815) Monotherapy Trial Dose Escalation Reported Phase 1 (N=41) Dose Expansion Accessible UV-induced Patients: Dose Escalation cancers Cutaneously ADU-S100 accessible, treatment- ADU-S100 Dose Selection refractory, advanced (Days 1, 8, 15, q4w) Dose Expansion or metastatic solid

  10. Slide 10: ADU-S100 Monotherapy Trial Baseline Patient Demographics

    Phase 1 ADU-S100 (MIW815) Monotherapy Trial Baseline Patient Demographics All Patients (N=41) Prior therapy Number of prior Median age Sex Race ECOG PS with a checkpoint regimens years (range) n (%) n (%) n (%) inhibitor n (%) n (%) 62 Male Caucasian 0 Yes 0 (26–80) 18 (43.9) 27 (65.9) 11 (26.8) 22

  11. Slide 11: ADU-S100 Monotherapy Trial Safety and Tolerability

    Phase 1 ADU-S100 (MIW815) Monotherapy Trial Safety and Tolerability Adverse Event % • No DLTs observed during the first cycle of >1 any AE 78.0 treatment Led to discontinuation 0.0 – No patients discontinued treatment due to an AE Grade >3 12.2 Led to death 0.0 • Elevated lipase was the only Grade 3

  12. Slide 12: ADU-S100 Monotherapy Trial Time on Treatment and Response Evaluation

    Phase 1 ADU-S100 (MIW815) Monotherapy Trial Time on Treatment and Response Evaluation 12 Meric-Bernstam et al. Phase I Dose-finding Study of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced Solid Tumors or Lymphomas. Poster presented at: The Society for Immunotherapy of Ca

  13. Slide 13: ADU-S100 Monotherapy Trial Time on Treatment and Response Evaluation

    Phase 1 ADU-S100 (MIW815) Monotherapy Trial Time on Treatment and Response Evaluation 13 Meric-Bernstam et al. Phase I Dose-finding Study of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients With Advanced Solid Tumors or Lymphomas. Poster presented at: The Society for Immunotherapy of Ca

  14. Slide 14: Systemic Signals of STING Target Engagement

    Phase 1 ADU-S100 (MIW815) Monotherapy Trial Systemic Signals of STING Target Engagement: IL-6, MCP1 and IFN-β Systemic cytokines consistently observed > 800 mcg Cytokines trend higher with repeat dosing 14

  15. Slide 15: Data Highlights from ADU-S100 Monotherapy Trial

    Data Highlights from Phase 1 ADU-S100 (MIW815) Monotherapy Trial Good safety profile Well-tolerated in heavily pre-treated, heterogenous patient population Preliminary signs • 2 of 40 patients treated had a PR, one patient received prior of clinical and anti-PD-1 therapy biomarker activity • 11 pati

  16. Slide 16: Phase 1b ADU-S100 + spartalizumab Trial

    Phase 1b ADU-S100 (MIW815) + spartalizumab (PDR001) Trial Ongoing Phase 1b Patients: Dose Escalation Dose Expansion Cutaneously ADU-S100 (Days 1, 8, 15 q4w) PD-1 R/R Melanoma accessible, treatment- PDR001 (Day 1 q4w) PD-1 R/R SCCHN ADU-S100 refractory, advanced Dose or metastatic solid Selection tum

  17. Slide 17: Preliminary Observations from Phase 1b ADU-S100 + spartalizumab Trial

    Preliminary Observations from Phase 1b ADU-S100 (MIW815) + spartalizumab Trial 50 patients enrolled; Patients treated with full-dose PDR001 and increasing dosing Dose escalation ongoing of intratumoral ADU-S100 (50-400mcg) Safety profile consistent with No DLTs have been reported monotherapy study •

  18. Slide 18: Clinical Observations to-date Support MOA of ADU-S100

    Clinical Observations to-date Support MOA of ADU-S100 (MIW815) Dose expansions and further exploration in homogenous populations – important next steps to assess ADU-S100 (MIW815) potential Monotherapy + spartalizumab + ipilimumab + anti-PD1 (ongoing) (ongoing) (enrolling) (planned) • First in human

  19. Slide 19: BION-1301 APRIL Antibody

    BION-1301 y APRIL Antibody ou Seal _ ADUR' BIOTEC.

  20. Slide 20: Multiple Myeloma Cell Survival Enhanced by APRIL in Bone Marrow Niche

    Multiple Myeloma Cell Survival and Proliferation Enhanced by APRIL Produced in Bone Marrow Niche • APRIL: Ligand A Proliferation Inducing APRIL áAPRIL mAb Bone Marrow Binds BCMA – Soluble factor that binds to BCMA BCMA and TACI receptors and induces signaling MM Cells Proliferation of MM Cells áAPRI

  21. Slide 21: Key Attributes of BION-1301

    Key Attributes of BION-1301 First-in-Class APRIL Antibody APRIL • both BION-1301 receptors fully BCMA blocking and antibody, TACI blocks APRIL binding to • Preclinical MM data support biological and scientific rationale in and expansion into combinations and adjacent cancer indications – Blocking AP

  22. Slide 22: Phase 1/2 BION-1301 Multiple Myeloma Trial

    Phase 1/2 BION-1301 Multiple Myeloma Trial Ongoing Phase 1/2 Patients: Relapsed/Refractory multiple Phase 1 BION-1301 myeloma whose disease has Dose Ph2 Phase 2 progressed after at least 3 prior systemic therapies Escalation Dose & Dose Schedule Expansion BION-1301 Selection Primary Objective: (Days

  23. Slide 23: BION-1301 Mechanism of Action in IgA Nephropathy

    BION-1301 Mechanism of Action has Potential to Affect Multiple Steps of IgA Nephropathy Pathogenesis High unmet medical need and no approved drugs for IgA Nephropathy BION-1301 Pietro A. Canetta et al. CJASN 2014 23

  24. Slide 24: Preclinical Data Provides Rationale for BION-1301 in IgA Nephropathy

    Preclinical Data Provides Compelling Rationale for BION-1301 in IgA Nephropathy Mice Non Human Primates Time after start study, week 24

  25. Slide 25: Phase 1 BION-1301 Trial in Healthy Volunteers and IgAN Patients

    Phase 1 BION-1301 Trial in Healthy Volunteers and IgAN Patients First-in-Human study designed to enable dose selection and generate proof of mechanism data Single Dose (HVs only) Multiple Rising Dose High dose Dose 3 Follow-up IgAN Follow High dose Bioanalysis Dose 2 Bioanalysis Follow-up -up PK/PD

  26. Slide 26: Business Overview

    Business Overview ADURO BIOTECH.

  27. Slide 27: Aduro Strategic Collaborations and Partnerships

    Aduro Strategic Collaborations and Partnerships Program Collaboration Indication Terms Commercial • $700M upfront & • Aduro leads US sales ADU-S100 potential milestones • Profit/expense share U.S., and other Oncology • $50M equity major EU and Japan agonists • Co-development & • Royalties ROW co-com

  28. Slide 28: Strong Financial Position and Broad Intellectual Property Portfolio

    Strong Financial Position and Broad Intellectual Property Portfolio 3Q 2018 Financials Extensive Patent Portfolio Cash & cash equivalents as of $278.6M Global Rights (includes in-licensed patents) September 30, 2018 • >150 issued composition and methods patents • >300 pending applications Operating

  29. Slide 29: Upcoming Anticipated Milestones

    Upcoming Anticipated Milestones H1 H2 2019 2019 ADU-S100 + ipilimumab Initiate Phase 1 dose escalation in PD-1 R/R melanoma ADU-S100 + spartalizumab Initiate Phase 1 dose expansion STING ADU-S100 + spartalizumab Report Phase 1 dose escalation results ADU-S100 + anti-PD-1 Initiate Phase 1b/2 dose esc

  30. Slide 30: Aduro Biotech

    ADURO BIOTECH

Aduro Biotech — Investor Presentation (January 2019) on 6ix